AbCellera Investor Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 12 OUR PARTNERS LOOK TO US TO UNLOCK NEW TARGETS & NEXT-GEN MODALITIES TARGETS MODALITIES 28% DIFFICULT targets M Y 0 multi-pass membrane targets IgGs, IgMs, IgAs CAR-T cell therapies radioisotope conjugates CNS-directed antibodies high homology targets Y bispecific antibodies anti-CD3 antibodies 72% STANDARD targets 83 & peptide-MHC targets Y single domains (VHH)

View entire presentation